Back to Top Skip to main content Skip to sub-navigation

DOD Pharmacy and Therapeutics Committee 2021

The Department of Defense Pharmacy & Therapeutics (DOD P&T) Committee's mission is to uniformly, consistently, and equitably provide appropriate drug therapy to meet the clinical needs of DOD beneficiaries in an effective, efficient, and fiscally responsible manner. 

To learn more, please see the Dec 2004 Health Affairs Policy 04-032, TRICARE Pharmacy Benefit Formulary Management (clarified 22 Mar 2005).

DOD P&T Committee Meeting Schedule

View DOD P&T Meeting Minutes See Archived Meeting Pages


November 3-4, 2021

Uniform Formulary Request for Quote Information (Class Review) 

Uniform Formulary Request for Quote Information (Newly Approved Drugs)

  • UF BPA & UF ADP RFQ Documents Posted: August 2, 2021
  • Pre-Proposal Teleconference: August 11, 2021 @ 1300 Central
  • Clinical/Cost Presentation Meeting Window: (no clinical presentations requested)
  • UF BPA & UF ADP Class Quotes Due: September 23, 2021

 

Class Review Designated Newly Approved Drugs Drugs in Previously Reviewed Classes
  • CONTINUOUS GLUCOSE MONITORING SYSTEMS: THERAPEUTIC AGENTS:
    • Dexcom G6 Suite
    • Libre 2 Suite
  • IMMUNOLOGICAL AGENTS MISCELLANEOUS: SUBCUTANEOUS IMMUNE GLOBULINS:
    • Cutaquig
    • Cuvitru
    • Gammagard Liquid
    • Gammaked
    • Gamunex-C
    • Hizentra
    • Hyqvia
    • Hyqvia Ig Component
    • Xembify

*Please note that all agents in the class, including brands and all generics, may be considered for formulary management actions. Additionally, if a drug is approved prior to 27 August 2015, but not currently available the committee may still make a formulary recommendation.

 

    August 4-5, 2021

    Uniform Formulary Request for Quote Information (Class Review) 

    Uniform Formulary Request for Quote Information (Newly Approved Drugs)

    • UF BPA & UF ADP RFQ Documents Posted: April 30, 2021
    • Pre-Proposal Teleconference: May 12, 2021 @ 1300 Central
    • Clinical/Cost Presentation Meeting Window: (no clinical presentations requested)
    • UF BPA & UF ADP Class Quotes Due: June 24, 2021

     

    Class Review  Designated Newly Approved Drugs Drugs in Previously Reviewed Classes 
    • LEUKEMIA AND LYMPHOMA AGENTS:  BRUTON TYROSINE KINASE INHIBITORS :
      • Brukinsa
      • Calquence
      • Imbruvica
    • LAXATIVES-CATHARTICS-STOOL SOFTENERS:  BOWEL PREPARATIONS :
      • Clenpiq
      • Colyte With Flavor Packets
      • Gavilyte-N
      • Gavilyte-C
      • Gavilyte-G
      • Golytely
      • Moviprep
      • Nulytely
      • Nulytely With Flavor Packets
      • Osmoprep
      • Plenvu
      • Prepopik
      • Suprep
      • Sutab

    * Please note that all agents in the class, including brands and all generics, may be considered for formulary management  actions.  Additionally, if a drug is approved prior to 27 August 2015, but not currently available the committee may still make a formulary recommendation. 

    • Accrufer
    • Empaveli
    • Exservan
    • Lumakras
    • Myfembree
    • Nextstellis
    • Qelbree
    • Roszet
    • Truseltiq
    • Wegovy
    • Xolair
    • Zegalogue
     

    May 5-6, 2021

    Uniform Formulary Request for Quote Information

    • UF BPA & UF ADP RFQ Documents Posted: February 5, 2021
    • Pre-Proposal Teleconference: February 10, 2021 @ 1300 Central
    • Clinical/Cost Presentation Meeting Window: (no clinical presentations requested)
    • UF BPA & UF ADP Class Quotes Due: March 25, 2021

     

    Class Review  Designated Newly Approved Drugs  Drugs in Previously Reviewed Classes 
    • SLEEP DISORDERS - INSOMNIA:
      • Ambien
      • Ambien CR
      • Belsomra
      • Dayvigo
      • Edluar
      • Hetlioz
      • Intermezzo
      • Lunesta
      • Rozerem
      • Silenor
      • Zolpimist
    • MENOPAUSAL HORMONE THERAPY - ORAL SINGLE AGENTS:
      • Estrace
      • Menest
      • Premarin
    • MENOPAUSAL HORMONE THERAPY - ORAL COMBINATION AGENTS:
      • Activella
      • Angeliq
      • Bijuva
      • Covaryx
      • Covaryx H.S.
      • Eemt
      • Eemt H.S.
      • Femhrt
      • Lopreeza
      • Prefest
      • Premphase
      • Prempro
    • MENOPAUSAL HORMONE THERAPY - VAGINAL:
      • Estrace
      • Estring
      • Femring
      • Imvexxy
      • Premarin
      • Vagifem
      • Yuvafem

    * Please note that all agents in the class, including brands and all generics, may be considered for formulary management  actions.  Additionally, if a drug is approved prior to 27 August 2015, but not currently available the committee may still make a formulary recommendation. 

     
    • Bronchitol
    • Elepsia XR
    • Fotivda
    • Gemtesa
    • Klisyri
    • Lupkynis
    • Ponvory
    • Reditrex
    • Tepmetko
    • Tepmetko
    • Thyquidity
    • Tyblume
    • Ukoniq
    • Verquvo
    • Vesicare LS
    • Vocabria
     

    February 3-4, 2021

    Uniform Formulary Request for Quote Information

    • UF BPA & UF ADP RFQ Documents Posted: November 6, 2020
    • Pre-Proposal Teleconference: November 13, 2020 @ 1300 Central
    • Clinical/Cost Presentation Meeting Window: (no clinical presentations requested)
    • UF BPA & UF ADP Class Quotes Due: December 18, 2020

     

    Class Review Designated Newly Approved Drugs  Drugs in Previously Reviewed Classes
    • PULMONARY-3 AGENTS - COMBINATION

      • Breztri Aerosphere  
      • Trelegy Ellipta 

    • BREAST CANCER AGENTS - CYCLIN DEPENDENT KINASE INHIBITORS 
      • Ibrance  
      • Kisqali  
      • Kisqali Femara Co-Pack  
      • Verzenio

    *Please note that all agents in the class, including brands and all generics, may be considered for formulary management  actions.  Additionally, if a drug is approved prior to 27 August 2015, but not currently available the committee may still make a formulary recommendation. 

    • Alkindi Sprinkle
    • Eysuvis 
    • Imcivree
    • Impeklo
    • Nyvepria
    • Qdolo
    • Orgovyx
    • Orladeyo
    • Sutab
    • Winlevi
    • Wynzora
    • Zokinvy

     

    • Dexilant

    Subject to Change Disclaimer

    The Defense Health Agency (DHA) reserves the right to change the classes, sub-classes and/or designated new drugs, and other requirements, of whatever kind, affecting solicitations. The provisions of this table do not constitute a contract, express or implied, between the DHA and manufacturer or eligible bidder.

    If the DOD P&T Committee is unable to complete an evaluation of any of the drug classes, the Committee will continue its efforts at the next meeting.

    DHA Address: 7700 Arlington Boulevard | Suite 5101 | Falls Church, VA | 22042-5101

    Some documents are presented in Portable Document Format (PDF). A PDF reader is required for viewing. Download a PDF Reader or learn more about PDFs.